Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

Exclusion Criteria

• •1. Prior treatment failure or resistance to pirtobrutinib or BCL2 inhibitors.
• •2. Prior Anticancer Therapy:Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.Traditional Chinese herbal medicine with antitumor indications.Small-molecule targeted therapy within 2 weeks before study treatment initiation. ADCs or cytotoxic therapy within 10 weeks before study treatment initiation.
• •3. Participation in another investigational drug study within 4 weeks prior to the first dose of study treatment.
• •4. Systemic corticosteroid therapy (\>5 days within 14 days prior to treatment) at doses exceeding \>10 mg/day dexamethasone (or equivalent) for CNS disease control.
• •5. Requiring ongoing anticancer therapy.
• •6. Uncontrolled or Severe Cardiovascular Disease,
• •7. Active infection requiring IV antibiotics or systemic antimicrobial therapy.
• •8. Active HBV/HCV:Exceptions. Inactive HBsAg carriers, HBV patients with sustained viral suppression (HBV-DNA \< LLOD),HCV-cured patients are allowed.
• •9. Clinically significant abnormalities affecting drug absorption or prior total gastrectomy/gastric banding.
• •10. History of hemorrhagic diathesis or requirement for long-term oral anticoagulation.
• •11. Prior allogeneic hematopoietic stem cell transplantation (HSCT) or planned allogeneic HSCT.
• •12. Women who are pregnant or breastfeeding.
• •13. Known allergy to the study drug or its excipients.
• •14. Active psychiatric illness or history of alcohol/drug abuse .
• •15. Any uncontrolled illness, organ dysfunction, or medical condition that, in the investigator's judgment, jeopardizes patient safety or adherence to study procedures.
• •16. Other conditions deemed inappropriate for study participation by the investigator.